Monitor upcoming topline data from the C-BEYOND trial (mid-2026) and C-FORWARD trial (year-end 2026) as key catalysts. The cash burn rate suggests potential need for financing before late 2027, assuming no near-term revenue generation.
Price Chart
Executive Summary
Atea Pharmaceuticals reported financial results for Q4 and full year 2025, highlighting continued advancement of its Phase 3 HCV program and expansion into a new Hepatitis E virus (HEV) program. The company reported a net loss of $158.3 million for the year, with R&D expenses increasing to $148.0 million, while cash and investments declined to $301.8 million from $454.7 million in 2024.
Key Financial Metrics
Key Facts
- Net loss for full year 2025 was $158.3 million, compared to $168.4 million in 2024
- Research and development expenses increased to $148.0 million in 2025 from $144.1 million in 2024
- Cash and investments declined to $301.8 million as of December 31, 2025, from $454.7 million as of December 31, 2024
- C-BEYOND Phase 3 trial enrollment completed in December 2025 with over 880 patients; topline results expected mid-2026
- C-FORWARD Phase 3 trial enrollment expected to complete mid-2026; topline results anticipated year-end 2026
- Company selected AT-587 as lead candidate for HEV program; clinical development expected to begin mid-2026
Financial Impact
Cash position decreased by $152.9 million year-over-year, while R&D spending increased by $3.9 million despite winding down of COVID-19 program
Risk Factors
- High cash burn rate with $301.8 million in cash as of December 2025, raising potential future dilution concerns
- Clinical trial delays or negative results in Phase 3 HCV program could significantly impact valuation
- No revenue-generating products currently, with dependence on successful clinical development and regulatory approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-093961 |
| Document: d118938d8k.htm | 0001193125-26-093961 |
| Document: 0001193125-26-093961-index-headers.html | 0001193125-26-093961 |
| Document: 0001193125-26-093961-index.html | 0001193125-26-093961 |
| Document: 0001193125-26-093961.txt | 0001193125-26-093961 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | SC 13G | $5.01 | awaiting T+60 | — | $4.17 (−16.77%) |
Jul 14, 2026 15w ago | Press Release | $4.70 $5.01 | ▲ +6.60% | ▲ +3.22% | $4.17 (−11.28%) |
May 12, 2026 24w ago | Press Release | $4.57 $5.25 | ▼ −14.88% | ▼ −10.44% | $4.17 (+8.75%) |
Apr 27, 2026 26w ago | DEFA14A | $5.58 $4.75 | ▼ −14.87% | ▼ −18.86% | $4.17 (−25.27%) |
Mar 5, 2026 33w ago | 8-K | $5.89 $4.38 | ▼ −25.64% | ▼ −38.42% | $4.17 (−29.20%) |
Mar 5, 2026 33w ago | Press Release | $5.89 $4.38 | ▼ −25.64% | ▼ −38.42% | $4.17 (−29.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers